Following the receipt of updated shares in issue information for Harbin Pharmaceutical Group (China constituent), FTSE announces the following changes: | INDEX | CHANGE | EFFECTIVE FROM
START OF TRADING | | FTSE China A 400 Index | Harbin Pharmaceutical Group (A) (China, 6409883, 600664) will remain in the index with an increased shares in issue total of 1,917,483,289 and a decreased investability weighting of 50%.
| 7 February 2012 | | FTSE China A 600 Index | Harbin Pharmaceutical Group (A) will remain in the index as detailed above. | 7 February 2012 | | FTSE China A 600 Style Index | Harbin Pharmaceutical Group (A) will remain in the index as detailed above. | 7 February 2012 | | FTSE China A All-Share Index | Harbin Pharmaceutical Group (A) will remain in the index as detailed above. | 7 February 2012 | | FTSE China A High Yield 150 Index | Harbin Pharmaceutical Group (A) will remain in the index with an increased shares in issue total of 1,917,483,289 and a decreased investability weighting of 50% and a decreased portfolio weighting of 61.28%. | 7 February 2012 |
Please note all the above changes will be reflected in the FTSE China A Galaxy Provincial Indices. For index related enquiries or further information about FTSE China Index Series please contact: | Client Services in UK: | Tel: +44 (0) 20 7866 1810 | | Client Services in US: | Tel: +1 888 747 FTSE (3873) or +1 212 314 1139 | | Client Services in Asia Pacific: | Tel: +852 2164 3333 or +65 6223 3738 or +81 3 3581 2764 |
Or, email your enquiries to info@ftse.com or visit our website at www.ftse.com. |
